The Gilmartin Group is a strategic consulting firm focused on investor relations, communications and business development for companies across the healthcare and life sciences space. Our goal is to help our clients create durable long term value by leveraging our team’s capital markets experience, communications expertise and deep industry knowledge.
External link for Gilmartin Group LLC
San Francisco Bay Area, CA 94920, US
New York, US
San Diego, CA, US
Gilmartin Group LLC reposted this
Gilmartin Group CEO & Founder Lynn Pieper Lewis moderated a panel on Research Analysts' Perspectives at the Piper Sandler & Latham & Watkins IPO Summit in Laguna Beach yesterday. We enjoyed connecting with everyone at this productive and insightful event. A big thank you to our friends at Piper Sandler for having us.
Gilmartin Group CEO & Founder Lynn Pieper Lewis moderated a panel on Research Analysts' Perspectives at the Piper Sandler & Latham & Watkins IPO Summit in Laguna Beach yesterday. We enjoyed connecting with everyone at this productive and insightful event. A big thank you to our friends at Piper Sandler for having us.
Did you miss this quarter's MedTech Newsletter? In the latest publication, we're reflecting on Q2, featuring a special interview with Sustainable Governance Partners on 2024 proxy season highlights. Subscribe to Gilmartin Group's MedTech Quarterly Newsletter for the latest updates on MedTech sector insights, financings and M&A activity, valuation and upcoming conferences. Subscribe to the newsletter: https://lnkd.in/gPZT2RGZ
Congratulations to Fractyl Health who presented compelling preclinical Rejuva data at #ADA 2024 last weekend, which was selected as the #1 abstract out of 8,000 submissions.
WEBINAR: Please join Gilmartin Managing Director Ryan Halsted and guest speakers Sean Dodge, CFA, Director, RBC and Jailendra Singh, Managing Director, Truist on Thursday July 11 for a webinar on The Current State and Outlook for Value-Based Care Across Healthcare Services & Tech. Elevated healthcare utilization trends combined with funding pressures resulting from regulatory and policy changes have raised recent questions about the investability of Medicare Advantage organizations and key value-based care (VBC) provider groups. However, the long-term position of value-based care within the government payor landscape is expected to only continue to expand. In this webinar, we will be discussing the current state and outlook of value-based healthcare. How should companies across the Services and Healthcare IT sectors be best messaging and positioning their value proposition to VBC? What are key innovations that you are most excited about and believe will likely to contribute the most to VBC’s evolution? Registration is required. -- #healthcareit #hcit #healthtech #webinar #VBC
This content isn’t available here
Access this content and more in the LinkedIn app
GILMARTIN BLOG: In today's blog post, Gilmartin Principal Kiki Patel, PharmD is discussing biotech sector trends and the return of the #PIPE in 2024. While there may be sector specific factors leading to heightened market volatility, much of the unpredictability is a product of the macroeconomic headwinds of the Fed’s restrictive monetary policy, geopolitical tensions, and a major presidential election looming around the corner. As fresh powder is drying up, companies are now starting to tap into alternative methods of financing. According to data from Evercore, U.S. biotechs have raised $5.5 billion through private investment in public equity deals, commonly known as PIPEs, in 2024. Read the full blog post: https://lnkd.in/g_PQRX4B
At Gilmartin, we are committed to fostering an inclusive and diverse workplace where every individual feels valued, respected, and empowered to bring their authentic selves to work each day. We recognize that diversity is not only a moral imperative but also a strategic advantage, driving innovation, creativity, and growth. This day serves as a moment of reflection, learning, and action as we work towards a brighter and more inclusive future.
GILMARTIN BLOG: In the latest Gilmartin Group blog post, we're discussing the State of the Union: Life Science Tools & Diagnostics, covering sector sentiment, valuations, M&A and sector consolidation and where the LSTDx sector is heading in the back half of 2024. To read more, check out the full blog post here: https://lnkd.in/gXpPv4tC
Congratulations to Silk Road Medical, Inc. on announcing a definitive agreement to be acquired by Boston Scientific. Silk Road Medical, Inc. (NASDAQ: SILK), is a medical device company that is focused on reducing the risk of stroke and its devastating impact. Official press release: https://lnkd.in/g73kn8Jv
Congratulations to Umoja Biopharma on announcing a publication in Blood, the flagship journal of the American Society of Hematology, highlighting the successful generation of in vivo CAR T-cells in non-human primate modeling. Umoja Biopharma, Inc. is a clinical-stage biotechnology company aiming to develop off-the-shelf therapeutics that improve the reach, effectiveness, and access of CAR T-cell therapies in both #oncology and #autoimmunity. Official press release: https://lnkd.in/g84tBtQ7